小血管病他达拉非治疗3个月后脑血流与认知(ETLAS-2):随机对照试验研究方案
ETLAS-2是一项2期双盲随机安慰剂对照平行试验,以他达拉非的可行性为主要结局,计划纳入100例小血管闭塞性卒中或短暂性脑缺血发作且伴脑小血管病征象的患者,在用药前至少6个月发病。患者接受他达拉非20 mg或安慰剂每日治疗3个月,通过MRI评估小血管病变化及脑血流、脑血管反应性和神经血管耦合,并进行认知测试。目前已完成64例入组,试验预计2024年完成。
要点
- ETLAS-2为2期双盲随机安慰剂对照平行试验,评估他达拉非20 mg每日治疗3个月的可行性。
- 计划纳入100例小血管闭塞性卒中或短暂性脑缺血发作且伴脑小血管病征象、发病至少6个月的患者。
- 通过MRI评估小血管病变化及脑血流、脑血管反应性、神经血管耦合,并进行认知测试。
核心结论
- ETLAS-2试验检验他达拉非长期治疗的可行性,并在子研究中探索其对脑小血管病血管和认知效应。
- 研究旨在提出新的治疗靶点并增进对脑小血管病的理解。
研究设计与样本
- 2期双盲、随机、安慰剂对照、平行试验,以他达拉非的可行性为主要结局。
- 计划纳入100例小血管闭塞性卒中或短暂性脑缺血发作且伴脑小血管病征象、发病至少6个月的患者。
- 患者每日接受他达拉非20 mg或安慰剂治疗3个月,并进行MRI评估及认知测试。
主要发现
- 目前已有64例患者入组,试验预计2024年完成。
关键数值与推荐
- 他达拉非20 mg每日治疗3个月,对照为安慰剂。
- 通过MRI按STRIVE标准评估小血管病变化,并在功能MRI子研究中评估脑血流、脑血管反应性和神经血管耦合。
- 认知子研究采用纸笔测试和剑桥神经心理学测试自动化成套测验(CANTAB)进行综合认知测试。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted treatment is highly warranted for cerebral small vessel disease, a causal factor of one in four strokes and a major contributor to vascular dementia. Patients with cerebral small vessel disease have impaired cerebral blood flow and vessel reactivity. Tadalafil is a specific phosphodiesterase 5 inhibitor shown to improve vascular reactivity in the brain. METHODS: The ETLAS-2 trial is a phase 2 double-blind, randomized placebo-controlled, parallel trial with the feasibility of tadalafil as the primary outcome. The trial aims to include 100 patients with small vessel occlusion stroke or transitory ischemic attacks and signs of cerebral small vessel disease more than 6 months before administration of study medication. Patients are treated for 3 months with tadalafil 20 mg or placebo daily and undergo magnetic resonance imaging (MRI) to evaluate changes in small vessel disease according to the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) criteria as well as cerebral blood flow, cerebrovascular reactivity, and neurovascular coupling in a functional MRI sub-study. The investigation includes comprehensive cognitive testing using paper-pencil tests and Cambridge Neuropsychological Test Automated Battery (CANTAB) tests in a cognitive sub-study. DISCUSSION: The ETLAS-2 trial tests the feasibility of long-term treatment with tadalafil and explores vascular and cognitive effects in cerebral small vessel disease in trial sub-studies. The study aims to propose a new treatment target and improve the understanding of small vessel disease. Currently, 64 patients have been included and the trial is estimated to be completed in the year 2024. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05173896. Registered on 30 December 2021.
引用
- Ölmestig J, Mortensen KN, Fagerlund B, et al. Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): study protocol for a randomized controlled trial. Trials. 2024. PMID: 39210472. doi:10.1186/s13063-024-08402-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。